Stony Brook Experts

an online search tool for members of the media to identify experts at Stony Brook

Search experts:

or

Browse experts:

View all departments View all topics View all experts Close
Michael Schuster Transplant Specialist, Hematologist/Oncologist, Professor of Medicine, Team Leader and Director, Bone Marrow and Stem Cell Transplantation, Director, Hematologic Malignancies Program Stony Brook Cancer Center Stem Cell Transplantation and Hematologic Malignancy Program School of Medicine

Contact Information

Health Sciences Center

Stony Brook, 11794

631/444-2448

Biography

Michael Schuster is a renowned hematologic cancer expert who has been the principal investigator for more than 200 clinical trials over the past 20 years and has worked extensively in the area of bone marrow transplantation, cytokines, hematologic malignancies, oncology new drug development, and cachexia. His research interests include improving stem cell transplant outcomes, new drug development in hematologic malignancies, lymphoma and leukemia, therapeutic uses of cytokines and immunotherapy, novel conditioning regimens in bone marrow, and blood stem cell transplantation, as well as the role of pro-inflammatory cytokines in geriatric and cancer cachexia, anemia, and in other disease states.

Education

  • Medical School, Dartmouth Medical School
  • Residency, Beth Israel Deaconess/Harvard Medical School, Internal Medicine
  • Fellowship, Beth Israel Deaconess/Harvard Medical School, Internal Medicine -Hematology/Oncology
  • Post-Doctoral Fellow, Harvard Medical School, Molecular Medicine

Research Grants

Award Start End Sponsor Type Amount Status
Phase IIB, Multicenter, Randomized, Open-Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adult Patients <65 Years Old with AML in First Relapse Following an Initial CR >1 Month Duratio 2010-10-06T00:00:00 2013-03-12T00:00:00 Celator Pharmaceuticals Incorporated Nonfederal 15319 Closed
Case BMT CTN: Antibacterial Prophylaxis In Post-Engraftment Allogeneic HCT 2012-07-01T00:00:00 2013-02-06T00:00:00 Case Western Reserve University Nonfederal 0 Closed
A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas 2011-01-10T00:00:00 2012-12-15T00:00:00 Aegera Therapeutics Incorporated Nonfederal 5500 Closed
An Open-Label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR), Through the Use of TH9402 and Light Treatment in an Ex Vivo Process, i 2011-10-18T00:00:00 2013-09-07T00:00:00 Kiadis Pharma Netherlands B V Nonfederal 8000 Closed
A Multicenter, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) 2012-11-21T00:00:00 2012-11-30T00:00:00 Case Western Reserve University Nonfederal 0 Closed
Pharmacokinetics, Safety and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1B) 2011-12-02T00:00:00 2014-04-10T00:00:00 Schering Plough Research Institute Nonfederal 12666.2 Closed
A Single-Arm, Open-Label, Multi-Center Study of Complete Molecular Response (CMR) in Adult Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) 2012-09-27T00:00:00 2014-05-23T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 4500 Closed
A Single-Arm, Multicenter, Nilotinib Treatment-Free Remission Study in Patients with BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib... 2013-10-02T00:00:00 2015-06-26T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 6875 Closed
A Multicenter, Open-Label, Phase 2, Safety and Efficacy Study of the Bruton's Tryosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory de Novo Diffuse Large B-Cell Lymphoma 2014-09-26T00:00:00 2015-09-26T00:00:00 Pharmacyclics Nonfederal 5000 Closed
Start Up Fees: Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic 2016-09-13T00:00:00 2017-09-12T00:00:00 Gilead Sciences Incorporated Nonfederal 6625 Approved
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B Lineage Acute Lymphoblastic Leukemia in Adults 2017-07-18T00:00:00 2018-07-18T00:00:00 Eastern Cooperative Oncology Group Nonfederal 1 Approved
International Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registry Data Collection 2007-07-02T00:00:00 2017-09-27T00:00:00 National Marrow Donor Program Nonfederal 38573 Approved
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell (PBSC) Transplant in Patients with Hodgkin Lymphoma or Non-Hodgkin Lymphoma Undergoing... 2010-11-12T00:00:00 2017-07-27T00:00:00 U S Biotest Incorporated Nonfederal 123964.83 On Hold
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs) 2011-05-03T00:00:00 2017-02-22T00:00:00 Merck and Company Nonfederal 116703 Closed
An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin Administered in Combination with Rituximab Compared to Defined Investigator's Choice Therapy in Subjects with Relapsed or Refractory CD22-Positive Aggressive Non-Hodgkin Lymp 2011-06-20T00:00:00 2016-02-23T00:00:00 Pfizer Incorporated Nonfederal 16513.78 Closed
A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients with First Relapsed of Refractory Acute Myeloid Leukemia (VALOR) 2011-08-01T00:00:00 2016-02-09T00:00:00 Sunesis Pharmaceuticals Incorporated Nonfederal 45861 Closed
BMS: Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5 Year Prospective Cohort Study (SIMPLICITY) 2011-09-16T00:00:00 2018-04-03T00:00:00 Icon Clinical Research Nonfederal 33584.91 Approved
A Phase I Study Evaluating the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects with Acute Leukemias and Related Disorders 2011-10-14T00:00:00 2016-06-10T00:00:00 Amgen Incorporated Nonfederal 100371.25 Closed
An International Randomized Controlled Study of Extracorporeal Photopheresis Therapy for the Treatment of Patients with Chronic Graft-versus-Host DIsease 2012-01-04T00:00:00 2016-07-22T00:00:00 Therakos Incorporated Nonfederal 5875 Closed
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia 2012-01-20T00:00:00 2017-12-19T00:00:00 Cyclacel Limited Nonfederal 32463 Approved
A Phase III, Randomized, Placebo-Controlled, Clinical Trial t Study the Safety and Efficacy, of V212 in Adult Patients with Solid Tumor or Hematopoietic Malignancy 2012-02-03T00:00:00 2016-03-25T00:00:00 Merck Sharp and Dohme Corporation Nonfederal 4400 Closed
TaiGen: Phase II, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease 2012-03-13T00:00:00 2015-12-23T00:00:00 Covance Nonfederal 377051.35 Closed
BMS: A Phase 3, Randomized, Open Label of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects with Prevsiouly Untreated Multiple Myeloma 2012-03-27T00:00:00 2015-12-15T00:00:00 Parexel International LLC Nonfederal 5375 Closed
BMS: A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma 2012-03-27T00:00:00 2014-01-11T00:00:00 Parexel International LLC Nonfederal 5375 Closed
An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL) 2013-02-07T00:00:00 2016-09-24T00:00:00 Pfizer Incorporated Nonfederal 6375 Closed
BMT Clinical Research Network Data Coordinating Center 2013-04-10T00:00:00 2018-03-09T00:00:00 National Marrow Donor Program Nonfederal 6976.5 Approved
A Phase 3 Multicenter Randomized Open Label Study to Compare the Efficacy & Safety of Pomalidomide, Bortezomib & Low Dose Dexamethasone Versus Bortezomib & Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma 2013-06-25T00:00:00 2017-02-19T00:00:00 Celgene Corporation Nonfederal 5875 Closed
BMS: Prospective REsearch Assessment in Multiple Myeloma: an OBservationaL Evaluation (PREAMBLE) 2013-08-23T00:00:00 2018-04-03T00:00:00 Parexel International LLC Nonfederal 36080 Approved
Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib 2013-10-07T00:00:00 2017-05-10T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 6375 Closed
TaiGen Biotechology Co. Ltd:A Phase II, Open-Label Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined with G-CSF with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease 2015-01-22T00:00:00 2017-12-05T00:00:00 Covance Nonfederal 182873.66 Approved
Pfizer:A Randomized, Double-Blind Phase 1B/2 Study of PF-04449913 in Combination with Azacitidine in Patients with Previously Untreated Intermediate-2 or High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with 20-30% Blasts.... 2015-05-27T00:00:00 2018-03-10T00:00:00 Icon Clinical Research Nonfederal 6625 Approved
Open-label, Randomized Study of SGI-110 vsTreatment Choice in Adults with Previously Untreated Acute Myeloid Leukemia Not Considered Candidates for Intensive Remission Induction Chemotherapy 2015-08-06T00:00:00 2018-06-27T00:00:00 Astex Pharmaceuticals Incorported Nonfederal 72655.5 Approved
A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion 2015-08-14T00:00:00 2017-07-13T00:00:00 Gilead Sciences Incorporated Nonfederal 6625 Closed
Prospective, Open-Label, Multicenter, Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and GDC-0199 (ABT-199) Vs. Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL... 2015-09-15T00:00:00 2017-08-17T00:00:00 Genentech Incorporated Nonfederal 6750 Closed
Genentech: A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine(BG)Inpatients With Previously Untreated Chronic Lymphocytic Leukemia 2015-09-25T00:00:00 2018-07-28T00:00:00 Pharmaceutical Research Associates Incorporated Nonfederal 31117.12 Approved
Onyx: Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma 2015-10-28T00:00:00 2018-06-27T00:00:00 Pharmaceutical Research Associates Incorporated Nonfederal 22467 Approved
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects with Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen 2015-11-19T00:00:00 2017-09-08T00:00:00 Ansun BioPharma Nonfederal 27799 Approved
A Multicenter Study of Ibrutinib and Lenalidomide in Combination with DA-EPOCH-R in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma 2016-02-03T00:00:00 2018-01-06T00:00:00 Pharmacyclics Nonfederal 15430.75 Approved
A Phase 2, Open-Label, Single-Arm, Intra-Subject Dose-Escalation Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimond in Subjects with Symptomatic Moderate or Severe Chronic GVHD... 2016-04-11T00:00:00 2018-03-09T00:00:00 Actelion Clinical Research Incorporated Nonfederal 8075 Approved
A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation 2016-05-23T00:00:00 2018-04-10T00:00:00 Astellas Pharma Global Development Incorporated Nonfederal 6625 Approved
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic-Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)Previously Treated with Hypomethylating Agents 2017-03-30T00:00:00 2018-01-17T00:00:00 Astex Pharmaceuticals Incorported Nonfederal 31624.3 Approved
Genentech: A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Atezoluzumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B-Cell Lymphoma 2017-04-10T00:00:00 2018-01-05T00:00:00 Covance Nonfederal 6625 Approved
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia 2017-04-18T00:00:00 2018-04-18T00:00:00 Astex Pharmaceuticals Incorported Nonfederal 6625 Approved
A Randomized, Double-Blind, Phase 3 Study of Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) 2017-04-24T00:00:00 2018-04-24T00:00:00 Pharmacyclics Nonfederal 6625 Approved
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects >or= 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDHI Mutation 2017-08-18T00:00:00 2018-08-03T00:00:00 Agios Pharmaceuticals Incorporated Nonfederal 7900 Approved
Bristol-Meyers Squibb: Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Myeliod Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States 2017-08-18T00:00:00 2018-08-09T00:00:00 InVentiv Health Clinical LLC Nonfederal 6625 Approved
Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma 2017-08-23T00:00:00 2018-08-23T00:00:00 Pharmacyclics Nonfederal 1 Approved
An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non Small Cell Lung Cancer 2017-09-13T00:00:00 2018-09-08T00:00:00 Incyte Corporation Nonfederal 1 Approved